I'd like to answer that by saying that there's assurance that the program is based on the current human pathogens importation regulations. In fact, these labs are already doing this, and it has not stopped them from doing research or innovation. We're trying to level the playing field by having all the other labs that are not importing being brought up to the same standard as these labs that are already importing.
If you remove risk group 2, what you're dealing with is that we are going to probably have to keep the importation regulations—which have risk group 2 in them—as is, and then you're going to have an unlevel playing field, of those who are acquiring things domestically versus those who are acquiring pathogens from abroad. SARS is a domestic pathogen at this point, for example.
So really, it is built on a current regulation.
The other concerns are about security clearance. We're saying you don't need it for level 2, and you can have people accompany specific scientists working at level 3, if their security clearance has not already gone through. There are inventory issues that people want to discuss, and cost implications, and those are the specifics we cannot necessarily work through until the programmatic details are in place. That's why it's much easier to deal with those in regulations than to specify them in the bill itself.